Ciulli et al. discovered a drug-like VHL ligand, VHL1 (VH032) 111, and then used VHL1 to design a JQ1-based PROTAC MZ1 (compound 9) (Figure 4B), resulting in the targeted degradation of BRD4 in cervical cancer cells, while minimizing the impact on BRD2/3 29. This evidence concerns the gene VHL and cervical carcinoma.